首页> 美国卫生研究院文献>Cancer Science >Effects of SMYD2‐mediated EML4‐ALK methylation on the signaling pathway and growth in non‐small‐cell lung cancer cells
【2h】

Effects of SMYD2‐mediated EML4‐ALK methylation on the signaling pathway and growth in non‐small‐cell lung cancer cells

机译:SMYD2介导的EML4-ALK甲基化对非小细胞肺癌细胞信号通路和生长的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A specific subtype of non‐small‐cell lung cancer (NSCLC) characterized with an EML4‐ALK fusion gene, which drives constitutive oncogenic activation of anaplastic lymphoma kinase (ALK), shows a good clinical response to ALK inhibitors. We have reported multiple examples implying the biological significance of methylation on non‐histone proteins including oncogenic kinases in human carcinogenesis. Through the process to search substrates for various methyltransferases using an in vitro methyltransferase assay, we found that a lysine methyltransferase, SET and MYND domain‐containing 2 (SMYD2), could methylate lysine residues 1451, 1455, and 1610 in ALK protein. Knockdown of SMYD2 as well as treatment with a SMYD2 inhibitor in two NSCLC cell lines with an EML4‐ALK gene significantly attenuated the phosphorylation levels of the EML4‐ALK protein. Substitutions of each of these three lysine residues to an alanine partially or almost completely diminished in vitro methylation of style="fixed-case">ALK. In addition, we found that exogenous introduction of style="fixed-case">EML4‐ style="fixed-case">ALK protein with the substitution of lysine 1610 to an alanine in these two cell lines reduced the phosphorylation levels of style="fixed-case">AKT, one of the downstream oncogenic molecules in the style="fixed-case">EML4‐ style="fixed-case">ALK pathway, and suppressed the growth of the two cell lines. We further showed that the combination of a style="fixed-case">SMYD2 inhibitor and an style="fixed-case">ALK inhibitor additively suppressed the growth of these two style="fixed-case">NSCLC cells, compared with single‐agent treatment. Our results shed light on a novel mechanism that modulates the kinase activity of the style="fixed-case">ALK fused gene product and imply that style="fixed-case">SMYD2‐mediated style="fixed-case">ALK methylation might be a promising target for development of a novel class of treatment for tumors with the style="fixed-case">ALK fused gene.
机译:一种以EML4-ALK融合基因为特征的非小细胞肺癌(NSCLC)特定亚型,它驱动间变性淋巴瘤激酶(ALK)的组成型致癌激活,显示出对ALK抑制剂的良好临床反应。我们已经报道了多个例子,这些例子暗示了甲基化对非组蛋白蛋白(包括人类致癌作用中的致癌激酶)的生物学意义。通过使用体外甲基转移酶测定法搜索底物中各种甲基转移酶的过程,我们发现,赖氨酸甲基转移酶SET和MYND域包含2(SMYD2)可以使ALK蛋白中的赖氨酸残基1451、1455和1610甲基化。击倒SMYD2以及在两个带有EML4-ALK基因的NSCLC细胞系中用SMYD2抑制剂处理均会显着减弱EML4-ALK蛋白的磷酸化水平。在 style =“ fixed-case”> ALK 的体外甲基化中,这三个赖氨酸残基中的每一个被丙氨酸取代的部分或几乎完全减少了。此外,我们发现外源引入 style =“ fixed-case”> EML 4- style =“ fixed-case”> ALK 蛋白,将赖氨酸1610替换为这两种细胞系中的丙氨酸降低了 style =“ fixed-case”> EML 中的下游致癌分子之一 style =“ fixed-case”> AKT 的磷酸化水平。 4- style =“ fixed-case”> ALK 途径,抑制了两种细胞系的生长。我们进一步表明, style =“ fixed-case”> SMYD 2抑制剂和 style =“ fixed-case”> ALK 抑制剂的组合可加性抑制这两种药物的生长与单药治疗相比, style =“ fixed-case”> NSCLC 细胞。我们的结果揭示了调节 style =“ fixed-case”> ALK 融合基因产物激酶活性的新机制,并暗示 style =“ fixed-case”> SMYD 2介导的 style =“ fixed-case”> ALK 甲基化可能是开发新型 style =“ fixed-case”> ALK肿瘤治疗方法的有希望的目标融合基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号